Literature DB >> 16754344

High-risk soft tissue sarcoma: clinical trial and hyperthermia combined chemotherapy.

Rolf D Issels1.   

Abstract

For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival. Systemic chemotherapy has been integrated either after (adjuvant) or before (neoadjuvant) optimal local treatment by surgery and radiotherapy in HR-STS. This short overview summarizes the results of the combination with regional hyperthermia as a new treatment strategy to open a new therapeutic window.

Entities:  

Mesh：

Year:  2006        PMID： 16754344     DOI： 10.1080/02656730600707793

Source DB:  PubMed          Journal:  Int J Hyperthermia        ISSN： 0265-6736            Impact factor:   3.914


  5 in total

1.  Mathematical formulation and analysis of the nonlinear system reconstruction of the online image-guided adaptive control of hyperthermia.

Authors:  Kung-Shan Cheng; Mark W Dewhirst; Paul F Stauffer; Shiva Das
Journal:  Med Phys       Date:  2010-03       Impact factor: 4.071

2.  [Consensus diagnosis and therapy of soft tissue sarcoma].

Authors:  Thomas Brodowicz; Gabriele Amann; Andreas Leithner; Arpad Sztankay; Franz Kainberger; Wolfgang Eisterer; Bernadette Liegl-Atzwanger; Franz Rachbauer; Thomas Rath; Michael Bergmann; Philipp T Funovics; Ferdinand Ploner; Reinhard Windhager
Journal:  Wien Klin Wochenschr       Date:  2011-10-28       Impact factor: 1.704

3.  MFH revisited: outcome after surgical treatment of undifferentiated pleomorphic or not otherwise specified (NOS) sarcomas of the extremities -- an analysis of 140 patients.

Authors:  Marcus Lehnhardt; Adrien Daigeler; Heinz H Homann; Vanessa Schwaiberger; Ole Goertz; Cornelius Kuhnen; Hans U Steinau
Journal:  Langenbecks Arch Surg       Date:  2008-06-27       Impact factor: 3.445

4.  [Importance of specialized centers in diagnosis and treatment of extremity-soft tissue sarcomas. Review of 603 cases].

Authors:  M Lehnhardt; A Daigeler; H H Homann; J Hauser; S Langer; L Steinsträsser; C Soimaru; A Puls; H U Steinau
Journal:  Chirurg       Date:  2009-04       Impact factor: 0.955

Review 5.  Prospects for NK Cell Therapy of Sarcoma.

Authors:  Mieszko Lachota; Marianna Vincenti; Magdalena Winiarska; Kjetil Boye; Radosław Zagożdżon; Karl-Johan Malmberg
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.